CTOs on the Move

Chattem, Inc.

www.chattem.com

 
Chattem, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Chattanooga, TN. To find more information about Chattem, Inc., please visit www.chattem.com
  • Number of Employees: 25-100
  • Annual Revenue: $250-500 Million
  • www.chattem.com
  • 1715 W 38th St
    Chattanooga, TN USA 37409-1248
  • Phone: 423.821.4571

Executives

Name Title Contact Details

Similar Companies

Michiana Behavioral Health Center

Michiana Behavioral Health Center is a Plymouth, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Village Health Works

Village Health Works is a non-profit organization that provides quality, compassionate, and dignified healthcare and education to improve the lives of individuals, contribute to resilient communities, and strengthen health and education systems.

Matrixx Initiatives Inc.

Matrixx Initiatives Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Scottsdale, AZ. To find more information about Matrixx Initiatives Inc., please visit www.matrixxinc.com

Impact Instrumentation

Impact Instrumentation is a West Caldwell, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.